Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: September 27, 2022

Details for Patent: 8,227,484

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,227,484 protect, and when does it expire?

Patent 8,227,484 protects NUEDEXTA and is included in one NDA.

This patent has seventy-five patent family members in twenty-one countries.

Summary for Patent: 8,227,484

Title:	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Abstract:	Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Inventor(s):	Yakatan; Gerald (Del Mar, CA), Berg; James (San Diego, CA), Pope; Laura (Carlsbad, CA), Smith; Richard Alan (La Jolla, CA)
Assignee:	Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA)
Application Number:	13/415,067
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,227,484
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,227,484

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	AB	RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF PSEUDOBULBAR AFFECT	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,227,484

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	399553	See Plans and Pricing
Australia	2003251971	See Plans and Pricing
Australia	2008201775	See Plans and Pricing
Australia	2010212348	See Plans and Pricing
Australia	2013202184	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson

Medtronic

Johnson and Johnson

Boehringer Ingelheim

McKinsey

Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.